Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.

Oncotarget · 2017 · PMC5356865 · PMID 27902970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

All three of these tumors also showed significant prolongation of survival following treatment with CFI-400945 compared to control, as did a fourth model, OCIP167 that showed borderline significant reduction in tumor weight at three weeks (Figure 2B ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.